APA (7th ed.) Citation

Subbiah, V., Lassen, U., Gasal, E., Burgess, P., & Wainberg, Z. A. (2020). Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. Lancet Oncology, 21(11), e516. https://doi.org/10.1016/S1470-2045(20)30625-2

Chicago Style (17th ed.) Citation

Subbiah, Vivek, Ulrik Lassen, Eduard Gasal, Paul Burgess, and Zev A. Wainberg. "Dabrafenib Plus Trametinib in Patients with BRAFV600E-mutated Biliary Tract Cancer - Authors' Reply." Lancet Oncology 21, no. 11 (2020): e516. https://doi.org/10.1016/S1470-2045(20)30625-2.

MLA (9th ed.) Citation

Subbiah, Vivek, et al. "Dabrafenib Plus Trametinib in Patients with BRAFV600E-mutated Biliary Tract Cancer - Authors' Reply." Lancet Oncology, vol. 21, no. 11, 2020, p. e516, https://doi.org/10.1016/S1470-2045(20)30625-2.